EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Current use and perspectives of PET imaging in Alzheimer's disease: A Spanish national survey

María Nieves Cabrera-Martín iD, Pablo Aguiar-Fernández, Valle Camacho-Martí, Edgar F Guillén-Valderrama iD, Julio Francisco Jiménez-Bonilla, José Antonio Lojo-Ramírez iD, Diego Alfonso López-Mora, Jordi A Matías-Guiu iD, Patricia Paredes-Rodríguez, Andrés Perissinotti, Javier Arbizu iD

Journal of Alzheimer's Disease Reports · 2026-04 · 10

DOI: 10.1177/25424823261437129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer's Disease Reports, online erschienen am 13.04.2026. Verfasst von María Nieves Cabrera-Martín und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC), Universidad Complutense de Madrid, Madrid…. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Novel therapies for Alzheimer's disease are expected to increase the demand for biomarkers. PET will likely play a central role in patient selection and treatment monitoring, requiring adequate infrastructure and trained professionals.

Objective

To assess the current status of Nuclear Medicine departments in Spain regarding organization, expertise, and available infrastructure.

Methods

We conducted a nationwide survey among Nuclear Medicine departments in Spain.

Results

Respondents averaged 19.8 years of professional experience; 62.0% had specific neuroimaging training and 76.0% reported high confidence in amyloid PET interpretation. Hospitals were mainly public (70.6%) and widely distributed geographically, and 73.0% reported having cognitive impairment units. Following the INVEAT plan, Spain currently has 147 PET scanners, although capacity varies: most centers operate one scanner and five reported having none. Amyloid PET is available in 77.0% of departments, with annual volumes ranging from fewer than 10 to more than 100 studies; 15.0% cannot perform amyloid PET due to regional limitations. Quantification tools are available in 41.3% of centers, although only 15.5% include quantitative metrics in reports, while 66.7% support the use of centiloid standardization. Nearly all respondents anticipate increased indications for amyloid PET (screening 83.7%; monitoring 68.5%) and support multidisciplinary collaboration (89.1% favor Neuroimaging Committees). About half report workforce needs, mainly nuclear medicine physicians (46.2%). Research activity in Alzheimer's disease is expected to increase (95.6%).

Conclusions

Most departments recognize the key role of amyloid PET for anti-amyloid therapy implementation and anticipate increased demand, highlighting the need to expand availability, implement quantification tools, and strengthen multidisciplinary collaboration.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseasePET/CTamyloid-PETanti-amyloidhealthcare

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC), Universidad Complutense de Madrid, Madrid, Spain.
  • Molecular Imaging and Medical Physics Group, Santiago de Compostela University Hospital, Santiago de Compostela, Spain.
  • Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Department of Nuclear Medicine, Clinica Universidad de Navarra, CCUN Applied Medical Research, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
  • Department of Nuclear Medicine, University Hospital Marqués de Valdecilla, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
  • Department of Nuclear Medicine, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

ORCID-Profile: María Nieves Cabrera-Martín, Edgar F Guillén-Valderrama, José Antonio Lojo-Ramírez, Jordi A Matías-Guiu, Javier Arbizu

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Cabrera-Martín, M. N., Aguiar-Fernández, P., Camacho-Martí, V., Guillén-Valderrama, E. F., Jiménez-Bonilla, J. F., Lojo-Ramírez, J. A., López-Mora, D. A., Matías-Guiu, J. A., Paredes-Rodríguez, P., Perissinotti, A., & Arbizu, J. (2026). Current use and perspectives of PET imaging in Alzheimer's disease: A Spanish national survey. Journal of Alzheimer's Disease Reports, 10. https://doi.org/10.1177/25424823261437129

Vancouver

Cabrera-Martín MN, Aguiar-Fernández P, Camacho-Martí V, Guillén-Valderrama EF, Jiménez-Bonilla JF, Lojo-Ramírez JA, et al. Current use and perspectives of PET imaging in Alzheimer's disease: A Spanish national survey. Journal of Alzheimer's Disease Reports. 2026;10. doi:10.1177/25424823261437129

BibTeX
@article{CabreraMartn2026,
  author = {Cabrera-Martín, María Nieves and Aguiar-Fernández, Pablo and Camacho-Martí, Valle and Guillén-Valderrama, Edgar F and Jiménez-Bonilla, Julio Francisco and Lojo-Ramírez, José Antonio and López-Mora, Diego Alfonso and Matías-Guiu, Jordi A and Paredes-Rodríguez, Patricia and Perissinotti, Andrés and Arbizu, Javier},
  title = {Current use and perspectives of PET imaging in Alzheimer's disease: A Spanish national survey},
  journal = {Journal of Alzheimer's Disease Reports},
  year = {2026},
  volume = {10},
  doi = {10.1177/25424823261437129}
}
Kostenlos starten →